Immunomic Therapeutics, Inc., To Present at Biotech Showcase™ 2015

Share Article

Immunomic Therapeutics will be presenting the current state of the Company and its significant progress over the past year on executing on its plan and building investor value

News Image
Dr. Hearl commented that, "2014 was a landmark year for ITI. We have made significant progress in our clinical studies, partnering initiatives and funding. We are poised for significant growth over the next year..."

Immunomic Therapeutics, Inc., (ITI), a pioneering vaccine company, announced today that Dr. William Hearl, the Company’s President and CEO, will be presenting at the Biotech Showcase™ 2015 conference in San Francisco, CA.

Details of Immunomic Therapeutics, Inc.’s presentation are as follows:

Event:         Biotech Showcase™ 2015
Date:          Tuesday, January 13th, 2015
Time:          9:30 AM
Track:         Track A – Hearst (4th floor)
Location:        Parc 55 Wyndham San Francisco Union Square Hotel

ITI will report on the significant progress the Company has made over the past year in clinical development, expansion of the early stage pipeline and partnering efforts. The presentation will include an update on the status of negotiations of company’s exclusive license and collaboration with a top pharmaceutical Company in Japan, to commercialize and market JRC2*-LAMP-vax, a novel best-in-class allergy vaccine for treating and preventing allergies induced by Japanese red cedar pollen.

Dr. Hearl commented that “2014 was a landmark year for ITI. We have made significant progress in our clinical studies, partnering initiatives and funding. We are poised for significant growth over the next year and look forward to an exciting 2015, moving forward with development of our lead product in Japan, while expanding the Company, advancing our exciting allergy pipeline and pharmaceutical partnerships. This year, we are not announcing any new fundraising but are happy to provide an update to those who have been following us.”

Co-produced by Demy-Colton Life Science Advisors and EBD Group, Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry’s largest annual healthcare investor conferences. Now in its seventh year, Biotech Showcase is expected to attract upwards of 1,500 attendees.

About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately held clinical stage biotechnology company headquartered in Lancaster, PA, with lab facilities in Rockville, MD. ITI is developing next generation vaccines based on the patented LAMP Technology. Our LAMP-vax platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. Our LAMP constructs have been validated in human clinical trials for cancer and have been applied to a wide breadth of targets including allergy, cancer and infectious diseases.

About Demy-Colton Life Science Advisors
Demy-Colton Life Science Advisors is focused exclusively on facilitating the growth of the life science industry. Now going into its fifth year, Demy-Colton has developed a number of high-value added conferences to address the business and development needs of the biotechnology industry; it provides partnering services and it has helped launch a unique investor website and newsletter. For more information please visit http://www.demy-colton.com.

About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group's partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success. For more information please visit http://www.ebdgroup.com or follow EBD Group on Twitter at twitter.com/ebdgroup.

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Sia Anagnostou

Melissa Kemp
@immunomix
Follow >
Immunomic Therapeutics, Inc
since: 09/2012
Like >
Immunomic Therapeutics, Inc.

Visit website